Gemzar and Gastrointestinal toxicity - a phase IV clinical study of FDA data

Summary:

Gastrointestinal toxicity is reported as a side effect among people who take Gemzar (gemcitabine hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Cisplatin, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Gastrointestinal toxicity when taking Gemzar. It is created by eHealthMe based on reports of 20,184 people who have side effects when taking Gemzar from the FDA, and is updated regularly.

What is Gemzar?

Gemzar has active ingredients of gemcitabine hydrochloride. It is often used in pancreatic carcinoma. eHealthMe is studying from 20,315 Gemzar users. Check the latest studies of Gemzar.

What is Gastrointestinal toxicity?

Gastrointestinal toxicity (damage to digestive tract by any substance) is found to be associated with 308 drugs and 343 conditions by eHealthMe. Check the latest studies of Gastrointestinal toxicity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 16, 2026

20,184 people reported to have side effects when taking Gemzar.
Among them, 15 people (0.07%) have Gastrointestinal toxicity.

Could Gemzar cause Gastrointestinal toxicity?

Among these 15 people:

How long have people been on Gemzar when they have Gastrointestinal toxicity? *

What is the gender of people who have Gastrointestinal toxicity when taking Gemzar? *

female: 70 %
male: 30 %

What is the age of people who have Gastrointestinal toxicity when taking Gemzar? *

What are other drugs people take besides Gemzar? *

What are other side effects people have besides Gastrointestinal toxicity? *

Pain In Extremity: 3 people, 20.00%
Rashes (redness): 3 people, 20.00%
Nausea (feeling of having an urge to vomit): 3 people, 20.00%
Haemoglobin Abnormal: 2 people, 13.33%
Diarrhea: 2 people, 13.33%
Cough: 1 person, 6.67%
Fatigue (feeling of tiredness): 1 person, 6.67%
Drug Ineffective: 1 person, 6.67%
Disease Progression: 1 person, 6.67%
Dehydration (dryness resulting from the removal of water): 1 person, 6.67%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 2 people, 13.33%
Breast Cancer Metastatic: 2 people, 13.33%
Small Intestine Carcinoma (cancer tumour of small intestine): 1 person, 6.67%
Metastases To Lung (cancer spreads to lung): 1 person, 6.67%
Malignant Respiratory Tract Neoplasm (cancer tumour of respiratory tract): 1 person, 6.67%
Cervix Carcinoma Stage Ii (cancer has spread beyond the cervix but not to the pelvic wall): 1 person, 6.67%
Bladder Cancer: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Gemzar and have Gastrointestinal toxicity?

- Check whether Gastrointestinal toxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gemzar:

Gemzar (20,315 reports)

Browse all side effects of Gemzar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gastrointestinal toxicity:

Gastrointestinal toxicity (308 drugs)

Browse all the conditions that are associated with Gastrointestinal toxicity:

Gastrointestinal toxicity (343 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gemcitabine hydrochloride (the active ingredients of Gemzar) and Gemzar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.